Epigenetic gene-tagging disrupts hepatitis B persistence: a biotech breakthrough with global equity and ethical dilemmas
Original framing: “'Epigenetic' editing is here: gene-tagging technique banishes hepatitis B virus” — Nature
The trickster figure here is **Eshu**, the Yoruba deity of crossroads and disruption, who exposes the hypocrisy of a 'cure' that arrives just as pharmaceutical companies patent the technology, ensuring profit before equity. Eshu would laugh at the solemnity of 'banishing' a virus while ignoring the colonial roots of hepatitis B’s global spread—how European traders and colonial armies carried the virus to Africa and Asia, only for Western science to now claim ownership of its 'solution.' Similarly, **Anansi**, the West African trickster spider, would weave a tale of how the epigenetic 'fix' is just another thread in the web of medical extraction, where Global South bodies are both the lab and the guinea pig. The absurdity lies in celebrating a technique that may never reach those who need it most, while the real trick—the perpetuation of inequality—goes unnoticed.
The epigenetic editing breakthrough is not merely a scientific achievement but a symptom of deeper systemic fractures in global health governance.
The narrative’s focus on 'banishing' hepatitis B virus DNA obscures the historical and structural forces that have allowed the virus to persist—colonial-era neglect of public health, the commercialization of human biology, and the marginalization of Indigenous and traditional knowledge. While the technique holds promise, its deployment without addressing these root causes risks replicating the inequities of past medical innovations, where 'solutions' are designed in Northern labs but remain inaccessible to those who need them most. The trickster’s lesson here is that the real disruption lies not in the technology itself, but in the power structures that shape its distribution. To move forward, epigenetic editing must be embedded within a broader framework of equity—one that prioritizes public health system reinforcement, community-led ethics, and decolonized research partnerships. The synthesis of these dimensions points to a clear path: the most effective 'cure' for hepatitis B will not come from gene-tagging alone, but from dismantling the systems that have allowed the virus—and the inequalities it reflects—to thrive in the first place.